Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccination for Recurrent Glioblastoma: A Phase II, Single Arm Trial

Neuro-Oncology

Volumn 16, Issue 5, 2014, Pages 758-759

  Bloch, Orin ^a   Parsa, Andrew T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VITESPEN; CANCER VACCINE; HEAT SHOCK PROTEIN;

CANCER RECURRENCE; COMPARATIVE STUDY; CONTRAST ENHANCEMENT; GLIOBLASTOMA; HEALTH CARE QUALITY; HEAT SHOCK; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; INTERVENTIONAL MAGNETIC RESONANCE IMAGING; LETTER; NATIONAL HEALTH ORGANIZATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALVAGE THERAPY; STUDY DESIGN; TERTIARY CARE CENTER; UNITED STATES; VACCINATION; BRAIN NEOPLASMS; FEMALE; MALE;

BRAIN NEOPLASMS; CANCER VACCINES; FEMALE; GLIOBLASTOMA; HEAT-SHOCK PROTEINS; HUMANS; MALE;

EID: 84899411363     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou054     Document Type: Letter

References (14)

1. Bloch O Han SJ Cha S et al. Impact of extent of resection for recurrent glioblastoma on overall survival: Clinical article. J Neurosurg. 2012;117:1032-1038
2. Lacroix M Abi-Said D Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis extent of resection and survival. J Neurosurg. 2001;95:190-198
3. McGirt MJ Chaichana KL Gathinji M et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110:156-162
4. Chamberlain MC. Convection-enhanced delivery of a transforming growth factor-beta2 inhibitor trabedersen for recurrent high-grade gliomas: Efficacy real or imagined?. in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142). Neuro Oncol. 2011;13: 558-559; author reply 561-552
5. Chamberlain MC. Treatment of glioblastoma with bevacizumab: Has a new standard therapy been Defined?. CNS Drugs. 2011;25:815-818
6. Chamberlain MC. Does quality of life supplant survival in patients with brain metastasis?. J Clin Oncol. 2013;31:2635
7. Chamberlain MC. Should erlotinib be coadministered with whole-brain radiotherapy in patients with brain metastases and non-small-cell lung cancer?. J Clin Oncol. 2013;31:3164-3165
8. Chamberlain MC. Does RTOG 9802 change practice with respect to newly diagnosed low-grade glioma?. J Clin Oncol. 2013;31: 652-653
9. Chamberlain MC. Should Dose-Intense Immnochemotherapy Be the New Standard of Care for Primary CNS Lymphoma?. J Clin Oncol. 2014
10. Chamberlain MC Eaton K. Is there a role for whole brain radiotherapy in the treatment of leptomeningeal metastases?. J Thorac Oncol. 2012;7:1204; author reply 1204-1205
11. Chamberlain MC Goulart BH. Are prognostic factors for leptomeningeal metastases defined sufficiently to permit tailored treatment?. J Thorac Oncol. 2013;8:e66-67
12. Chamberlain MC Silbergeld DL. Is graded prognostic assessment an improvement compared with radiation therapy oncology groups recursive partitioning analysis classification for brain metastases?. J Clin Oncol. 2012;30:3315-3316; author reply 3316-3317
13. Chamberlain MC Silbergeld DL. Surgery a prognostic marker for progression-free survival?. Neuro Oncol. 2012;14:390-391; author reply 391
14. Chi AS Chamberlain MC. Is there a role for bevacizumab in the treatment of glioblastoma?. Oncologist. 2013;18:1080-1082.